Suppr超能文献

COVID-19患者病情进展和病毒长期脱落的相关临床因素:一项多中心研究

Clinical Factors Associated with Progression and Prolonged Viral Shedding in COVID-19 Patients: A Multicenter Study.

作者信息

Feng Zhichao, Li Jennifer, Yao Shanhu, Yu Qizhi, Zhou Wenming, Mao Xiaowen, Li Huiling, Kang Wendi, Ouyang Xin, Mei Ji, Zeng Qiuhua, Liu Jincai, Ma Xiaoqian, Rong Pengfei, Wang Wei

机构信息

1Department of Radiology, Third Xiangya Hospital, Central South University, Hunan, China.

2Molecular Imaging Research Center, Central South University, Hunan, China.

出版信息

Aging Dis. 2020 Oct 1;11(5):1069-1081. doi: 10.14336/AD.2020.0630. eCollection 2020 Oct.

Abstract

Coronavirus disease 2019 (COVID-19) is a global pandemic associated with a high mortality. Our study aimed to determine the clinical risk factors associated with disease progression and prolonged viral shedding in patients with COVID-19. Consecutive 564 hospitalized patients with confirmed COVID-19 between January 17, 2020 and February 28, 2020 were included in this multicenter, retrospective study. The effects of clinical factors on disease progression and prolonged viral shedding were analyzed using logistic regression and Cox regression analyses. 69 patients (12.2%) developed severe or critical pneumonia, with a higher incidence in the elderly and in individuals with underlying comorbidities, fever, dyspnea, and laboratory and imaging abnormalities at admission. Multivariate logistic regression analysis indicated that older age (odds ratio [OR], 1.04; 95% confidence interval [CI], 1.02-1.06), hypertension without receiving angiotensinogen converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB) therapy (OR, 2.29; 95% CI, 1.14-4.59), and chronic obstructive pulmonary disease (OR, 7.55; 95% CI, 2.44-23.39) were independent risk factors for progression to severe or critical pneumonia. Hypertensive patients without receiving ACEI/ARB therapy showed higher lactate dehydrogenase levels and computed tomography (CT) lung scores at about 3 days after admission than those on ACEI/ARB therapy. Multivariate Cox regression analysis revealed that male gender (hazard ratio [HR], 1.22; 95% CI, 1.02-1.46), receiving lopinavir/ritonavir treatment within 7 days from illness onset (HR, 0.75; 95% CI, 0.63-0.90), and receiving systemic glucocorticoid therapy (HR, 1.79; 95% CI, 1.46-2.21) were independent factors associated with prolonged viral shedding. Our findings presented several potential clinical factors associated with developing severe or critical pneumonia and prolonged viral shedding, which may provide a rationale for clinicians in medical resource allocation and early intervention.

摘要

2019冠状病毒病(COVID-19)是一种全球大流行疾病,死亡率很高。我们的研究旨在确定与COVID-19患者疾病进展和病毒持续排出相关的临床危险因素。本多中心回顾性研究纳入了2020年1月17日至2020年2月28日期间连续收治的564例确诊COVID-19住院患者。使用逻辑回归和Cox回归分析临床因素对疾病进展和病毒持续排出的影响。69例患者(12.2%)发生了重症或危重症肺炎,在老年人以及入院时伴有基础疾病、发热、呼吸困难以及实验室和影像学异常的个体中发病率更高。多因素逻辑回归分析表明,年龄较大(比值比[OR],1.04;95%置信区间[CI],1.02 - 1.06)、未接受血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂(ACEI/ARB)治疗的高血压(OR,2.29;95% CI,1.14 - 4.59)以及慢性阻塞性肺疾病(OR,7.55;95% CI,2.44 - 23.39)是进展为重症或危重症肺炎的独立危险因素。未接受ACEI/ARB治疗的高血压患者在入院后约3天时的乳酸脱氢酶水平和计算机断层扫描(CT)肺部评分高于接受ACEI/ARB治疗的患者。多因素Cox回归分析显示,男性(风险比[HR],1.22;95% CI,1.02 - 1.46)、发病后7天内接受洛匹那韦/利托那韦治疗(HR,0.75;95% CI,0.63 - 0.90)以及接受全身糖皮质激素治疗(HR,1.79;95% CI,1.46 - 2.21)是与病毒持续排出相关的独立因素。我们的研究结果提出了几个与发生重症或危重症肺炎以及病毒持续排出相关的潜在临床因素,这可能为临床医生进行医疗资源分配和早期干预提供理论依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/802c/7505267/57b9429081f3/ad-11-5-1069-g1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验